, /PRNewswire/ -- (Nasdaq: ), a clinical-stage biopharmaceutical company focused on creating targeted therapies for clinically proven kinase targets in cancer, today announced that updated data from the ARROS-1 Phase 1/2 clinical trial of zidesamtinib and ALKOVE-1 Phase 1/2 clinical trial of NVL-655, will be presented during two oral presentations at the European Society for Medical Oncology (ESMO) Congress 2024 taking place , in . Details for the presentations are as follows: Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors 1253O Proffered paper session Saturday September 14, 2024, 9:40 – Barcelona Auditorium – Hall 2 Alexander Drilon, M.D.
(Memorial Sloan Kettering Cancer Center, ) Phase 1/2 ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumors 1256MO Mini oral session Saturday September 14, 2024, 10:30 – Santander Auditorium – Hall 5 Benjamin Besse, M.D., Ph.
D. (Institut Gustav Roussy, Villejuif, ) Additionally, the company will present new preclinical data further characterizing the intracranial activity of zidesamtinib during a poster session. The title is: Profiling of Zidesamtinib and Other ROS1 Inhibitors in an Intracranial CD74-ROS1 G2032R Preclinical Model 4811 Anupong Tangpeerachaikul (Nuvalent, Inc.
, , ) Zidesamtinib is a novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is designed to remain active in tumo.
